Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label in the Batch - FDA.gov
4/11/2022 12:00:00 AM3 yearsago
by Center for Drug Evaluation and Research
by Center for Drug Evaluation and Research
Mylan Pharmaceuticals Inc., a Viatris company, is voluntarily recalling one batch of its Insulin Glargine (Insulin glargineyfgn) Injection, 100 units/mL (U-100), which is packaged in a 10 mL vial that is inside a carton. This product is not the branded Semgle…
Summary Company Announcement Date: April 12, 2022 FDA Publish Date: April 12, 2022 Product Type: Drugs Reason for Announcement: Recall Reason Description Label may be missing on some vials … [+5070 chars]
full article...